PMID- 28687599
OWN - NLM
STAT- MEDLINE
DCOM- 20171017
LR  - 20180823
IS  - 1535-5667 (Electronic)
IS  - 0161-5505 (Linking)
VI  - 58
IP  - 10
DP  - 2017 Oct
TI  - PSMA Ligands for PET Imaging of Prostate Cancer.
PG  - 1545-1552
LID - 10.2967/jnumed.117.191031 [doi]
AB  - Targeting the prostate-specific membrane antigen (PSMA) with (68)Ga-labeled and
      (18)F-labeled PET agents has become increasingly important in recent years.
      Imaging of biochemically recurrent prostate cancer has been established as a
      widely accepted clinical indication for PSMA ligand PET/CT in many parts of the
      world because of the results of multiple, primarily retrospective, studies that
      indicate superior detection efficacy compared with standard-of-care imaging. For 
      high-risk primary prostate cancer, evidence is growing that this modality
      significantly aids in the detection of otherwise occult nodal and bone
      metastases. For both clinical indications in recurrent as well as in primary
      prostate cancer, preliminary data demonstrate a substantial impact on clinical
      management. Emerging data imply that intraprostatic tumor localization, therapy
      stratification, and treatment monitoring of advanced disease in specific clinical
      situations might become future indications. Current criteria for image reporting 
      of PSMA ligand PET are evolving given the expanding body of literature on
      physiologic and pathologic uptake patterns and pitfalls. This article intends to 
      give an educational overview on the current status of PSMA ligand PET imaging,
      including imaging procedure and interpretation, clinical indications, diagnostic 
      potential, and impact on treatment planning.
CI  - (c) 2017 by the Society of Nuclear Medicine and Molecular Imaging.
FAU - Schwarzenboeck, Sarah M
AU  - Schwarzenboeck SM
AD  - Department of Nuclear Medicine, Rostock University Medical Centre, Rostock,
      Germany sarah.schwarzenboeck@med.uni-rostock.de.
FAU - Rauscher, Isabel
AU  - Rauscher I
AD  - Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of
      Munich, Munich, Germany.
FAU - Bluemel, Christina
AU  - Bluemel C
AD  - Department of Nuclear Medicine, University Hospital Wurzburg, Wurzburg, Germany.
FAU - Fendler, Wolfgang P
AU  - Fendler WP
AD  - Department of Molecular and Medical Pharmacology, David Geffen School of Medicine
      at UCLA, Los Angeles, California.
AD  - Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, 
      Germany.
FAU - Rowe, Steven P
AU  - Rowe SP
AD  - Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins
      University School of Medicine, Baltimore, Maryland.
FAU - Pomper, Martin G
AU  - Pomper MG
AD  - Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins
      University School of Medicine, Baltimore, Maryland.
FAU - Asfhar-Oromieh, Ali
AU  - Asfhar-Oromieh A
AD  - Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg,
      Germany.
AD  - Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Centre,
      Heidelberg, Germany; and.
FAU - Herrmann, Ken
AU  - Herrmann K
AD  - Department of Molecular and Medical Pharmacology, David Geffen School of Medicine
      at UCLA, Los Angeles, California.
AD  - Klinik fur Nuklearmedizin, Universitatsklinikum Essen, Essen, Germany.
FAU - Eiber, Matthias
AU  - Eiber M
AD  - Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of
      Munich, Munich, Germany.
AD  - Department of Molecular and Medical Pharmacology, David Geffen School of Medicine
      at UCLA, Los Angeles, California.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170707
PL  - United States
TA  - J Nucl Med
JT  - Journal of nuclear medicine : official publication, Society of Nuclear Medicine
JID - 0217410
RN  - 0 (Antigens, Surface)
RN  - 0 (Ligands)
RN  - EC 3.4.17.21 (FOLH1 protein, human)
RN  - EC 3.4.17.21 (Glutamate Carboxypeptidase II)
SB  - IM
EIN - J Nucl Med. 2017 Nov;58(11):1881. PMID: 29093111
MH  - Antigens, Surface/*metabolism
MH  - Glutamate Carboxypeptidase II/*metabolism
MH  - Humans
MH  - Image Processing, Computer-Assisted
MH  - Ligands
MH  - Male
MH  - Positron Emission Tomography Computed Tomography/*methods
MH  - Prostatic Neoplasms/*diagnostic imaging/*metabolism/pathology/therapy
OTO - NOTNLM
OT  - PET/CT
OT  - PSMA
OT  - prostate cancer
EDAT- 2017/07/09 06:00
MHDA- 2017/10/19 06:00
CRDT- 2017/07/09 06:00
PHST- 2017/05/26 00:00 [received]
PHST- 2017/07/06 00:00 [accepted]
PHST- 2017/07/09 06:00 [pubmed]
PHST- 2017/10/19 06:00 [medline]
PHST- 2017/07/09 06:00 [entrez]
AID - jnumed.117.191031 [pii]
AID - 10.2967/jnumed.117.191031 [doi]
PST - ppublish
SO  - J Nucl Med. 2017 Oct;58(10):1545-1552. doi: 10.2967/jnumed.117.191031. Epub 2017 
      Jul 7.